Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens
1997

Clodronate Improves Bone Density in Post-Menopausal Breast Cancer Patients

Sample size: 121 publication Evidence: moderate

Author Information

Author(s): T Saarto, C Blomqvist, M Valimaki, P Makela, S Sarna, I Elomaa

Primary Institution: Helsinki University Central Hospital

Hypothesis

Does clodronate improve bone mineral density in post-menopausal breast cancer patients treated with antioestrogens?

Conclusion

Clodronate combined with antioestrogens significantly increases bone mineral density in post-menopausal breast cancer patients.

Supporting Evidence

  • Clodronate increased bone mineral density by 2.9% in the lumbar spine and 3.7% in the femoral neck at 2 years.
  • Patients receiving only antioestrogens showed no significant changes in bone mineral density.
  • Both tamoxifen and toremifene similarly prevented bone loss.

Takeaway

This study found that a medicine called clodronate helps women with breast cancer keep their bones strong when they take other treatments.

Methodology

121 post-menopausal breast cancer patients were randomized to receive either tamoxifen or toremifene with or without clodronate for 3 years, and bone mineral density was measured at baseline, 1 year, and 2 years.

Limitations

Data from 28 patients were excluded from analyses due to various reasons, including metastatic disease and protocol violations.

Participant Demographics

Post-menopausal women with early-stage breast cancer, aged around 61-62 years.

Statistical Information

P-Value

0.001 and 0.006

Confidence Interval

95%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication